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ABSTRACT
Interferon-b (IFN-b) is of benefit in the treatment of multiple sclerosis (MS) and experimental autoimmune
encephalomyelitis (EAE), but the mechanisms by which it exerts this beneficial effect remain uncertain. The
present data demonstrate that IFN-b therapy impairs the proliferative response to concanavalin A (ConA)
and myelin basic protein (MBP), decreases expression of the CD80 molecule on leukocytes of treated mice,
and may thereby impede the Th1 cell activation-promoting anergy in EAE. Moreover, IFN-b therapy in-
creases expression of the CTLA4 molecule, which induces a counterregulatory Th2 response. The reduction
of CD80 expression with concomitant increase of CTLA4 expression alters the course of EAE and may be
useful as a monitor in therapy with IFN-b.
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INTRODUCTION
INTERFERON-b (IFN-b) HAS BEEN SHOWN to reduce the fre-quency of clinical attacks, the activity of MRI lesions, and
the evolution of the disease in patients with multiple sclerosis
(MS).(1,2) Moreover, there is evidence that IFN-b directly mod-
ulates the immune response and reduces the severity of exper-
imental autoimmune encephalomyelitis (EAE),(3,4) which is a
demyelinating diseases of the central nervous system (CNS)
that is mediated by Th1 type CD41 lymphocytes and serves as
a model for MS.(5) The progression of MS and EAE correlates
with increasing levels of proinflammatory cytokines, such as
tumor necrosis factor-a (TNF-a), IFN-g, and interleukin-12
(IL-12), as well as a decrease in the levels of anti-inflamma-
tory (Th2 type) cytokines, such as IL-10, IL-4, and transform-
ing growth factor-b (TGF-b).(6) There is also evidence of an
effect of IFN-b on cytokine production. Levels of IFN-g,(7)
TNF-a,(8) and IL-12(9) decreased in patients with MS during
treatment with IFN-b as well as in the experimental model. On
the other hand, IFN-b enhanced the production of anti-inflam-
matory cytokines, such as IL-10(10,11) and TGF-b,(10,12) in pa-
tients with MS and in the EAE model.(3)
Two signals are needed for T cell activation. Binding of the
T cell receptor by a peptide/MHC complex provides the first,
and the second is provided by cytokines such as IL-2 and co-
stimulatory proteins such as CD80 and CD86 expressed on 
antigen-presenting cells (APCs).(13) In the EAE model, the
CD801 cells activate Th1 lymphocytes, and CD86 activates the
Th2 cells.(14) Moreover, cytotoxic T lymphocyte-associated
antigen 4 (CTLA4), a counterreceptor in addition to CD28 for
the B7 family of costimulatory molecules, is a negative regu-
lator of T cell activation.(15,16)
The present study investigates whether IFN-b affects the ex-
pression of costimulatory molecules (CD28, CD80, CD86, and
CTLA4), causing the consequent induction of anergy in EAE.
Because the EAE model presents many clinical and histologic
similarities with MS, this approach underlines the importance




Six-to-eight-week-old female SJL mice, which are highly
susceptible to the induction of EAE,(3,4) were obtained from
The Harlan Sprague Dawley Laboratory (Indianapolis, IN). The
1Neuroimmunology Unit–Department of Microbiology and Immunology, and 2Laboratório Marcadores Celulares, University of Campinas
(UNICAMP), Campinas-SP, Brazil.
animals were housed and maintained pathogen free in the uni-
versity animal facility. All procedures were carried out in ac-
cordance with the guidelines proposed by the Brazilian Coun-
cil on Animal Care (COBEA) and approved by the Ethical
Committee on Animal Experimentation (CEEA/UNICAMP).
Treatment with IFN-b
The mice were divided into two groups of 10. One group re-
ceived no IFN-b treatment (controls), and the other received
IFN-b (10,000 IU mouse/day, every other day, for a total of
30,000 IU on days 27, 25, and 22. On day 0, all mice were
immunized with myelin basic protein (MBP)/complete Fre-
und’s adjuvant (CFA).
Antigen, antibody, and recombinant cytokines
Mouse IFN-b (Cytimmune) was purchased from Lee Bio-
molecular Research Inc. (San Diego, CA). Monoclonal anti-
bodies (mAbs) anti-CD4, anti-CD8, anti-CD28, anti-CD80,
anti-CD86, and anti-CTLA4, conjugated to FITC or phycoery-
thrin (PE) were purchased from PharMingen (San Diego, CA).
MBP was purified from guinea pig spinal cords as previously
described.(17)
Immunization and induction of EAE
The mice were immunized with MBP. Each animal received
an injection in the flank of 400 mg MBP in 0.10 ml phosphate-
buffered saline (PBS) emulsified in an equal volume of CFA
containing 4 mg/ml Mycobacterium tuberculosis H37RA
(Difco, Detroit, MI), an immunization protocol that has been
previously described.(18) Mice were evaluated daily for signs of
disease and graded on the following scale: grade 1, limp tail;
grade 2, hind limb weakness; grade 3, plegia of both hind limbs;
grade 4, plegia of three or four limbs; grade 5, moribund.
Isolation of lymphocytes
Spleen and draining lymph node cells were minced through
a steel sieve in Hank’s buffer. Connective tissue fragments were
allowed to settle for 10 min at 4°C, and lymphocytes were 
sedimented from the supernatant by low-speed centrifugation
(170g for 10 min at 4°C).
Proliferation assay
For concanavalin A (ConA) or MBP stimulation, lympho-
cytes were cultured in RPMI 1640 with 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 100
U/ml penicillin, 100 U/ml streptomycin, 2% heat-inactivated
fetal bovine serum (FBS), and 5 3 1025 M 2-mercaptoethanol
(Sigma Chemical Co., St. Louis, MO). The optimal concentra-
tion of mitogens had been determined in pilot experiments es-
tablishing the dose-response pattern, involving various con-
centrations of ConA and MBP, with the optimums fixed at 2.5
mg/ml for ConA and 25.0 mg/ml for MBP. The lymphocytes
(2 3 105/well) were cultured for 48 h for ConA and 144 h for
MBP stimulation. The cultures were pulsed with 1 mCi 3H-
thymidine (Amersham, Buckinghamshire, U.K.) per well dur-
ing the last 16 h of culturing and then harvested (Cell Harvester,
Cambridge Technology, Cambridge, MA). Thymidine uptake
was measured in a scintillation counter (Beckman System, San
Jose, CA).
Flow cytometry
Single cell suspensions (1 3 106 cells/ml) were stained us-
ing anti-CD4, anti-CD8, anti-CD28, anti-CD80, anti-CD86, and
anti-CTLA4 mAbs conjugated to FITC or PE. The analysis was
performed using a Becton Dickinson FACScan (Becton Dick-
inson, Mountain View, CA).
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FIG. 1. Clinical scores of EAE in mice treated in vivo with
recombinant mouse IFN-b (rMuIFN-b). Treatment with 10,000
IU/day was given on days 27, 25, and 22, followed by im-
munization with MBP/CFA on day 0.
FIG. 2. Effect of IFN-b on proliferative response of lymph
node cells stimulated with MBP and ConA. SJL mice treated
or not with IFN-b in vivo were immunized, and lymph node
cells were cultured and stimulated in vitro with MBP (A).
Spleen cells from naive mice treated in vivo with IFN-b were
stimulated in vitro with ConA (B).
Statistical analysis
The statistical significance of the data was determined by a
Student’s t-test and a two-tailed Wilcoxon rank sum test. A p
value , 0.05 was considered significant.
RESULTS
Reduction of clinical signs of EAE by administration
of IFN-b
To examine the effect of IFN-b on EAE, two groups of mice
(10 per group) were immunized with MBP/CFA. One group
was treated with 30,000 IU IFN-b/mouse in three doses, start-
ing 7 days prior to immunization, and the other group served
as the untreated control. Administration of IFN-b caused a de-
lay in the onset of the disease and a much milder disease course
(maximum clinical score: immunized group 3.8 6 0.4 vs. 0.6 6
0.1 for the treated group, p , 0.001) (Fig. 1). No significant
difference in animal weight was noted between the IFN-b-
treated group and the control group.
Inhibition of T cell proliferation by IFN-b
The effects of in vivo administration of IFN-b on the in vitro
proliferative response to MBP of lymph nodes from MBP/CFA-
immunized mice (Fig. 2A) and of ConA-stimulated spleen cells
from nonimmunized mice are shown in Figure 2B. IFN-b ad-
ministration effectively inhibited the T cell response to MBP
(27,620 6 1,600 cpm) for nontreated group vs. 12,640 6 1,200
cpm for the treated group (p , 0.01) (Fig. 2A). Administration
of IFN-b also reduced the proliferative response of lympho-
cytes from nonimmunized mice stimulated with nonspecific mi-
togen ConA (61,420 6 2,620 cpm and 37,840 6 2,400 cpm for
the nontreated and treated group, p , 0.01) (Fig. 2B).
Modification of expression of costimulatory molecules
by in vivo administration of IFN-b
As IFN-b administration prior to MBP/CFA lessened the
severity of EAE and suppressed the in vitro proliferative re-
sponse, the ability of IFN-b to modify costimulatory molecule
expression was examined. The in vivo administration of IFN-b
inhibited the expression of CD80 in the treated group compared
with immunized and naive groups (naive mice 6.5% 6 1.2% vs
18% 6 0.8% in the immunized group and 7.8% 6 0.6% in the
immunized and treated group, p , 0.001). There were no sig-
nificant changes in the expression of CD28 (p . 0.05). More-
over, there was no significant change observed among the three
groups in the expression of CD86 (p . 0.05) (Fig. 3).
The expression of CTLA4 was determined in the immunized
group treated or not with IFN-b 24 h after the last dose of 10,000
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FIG. 3. Costimulatory molecule expression on leukocytes of SJL mice treated or not with IFN-b. Lymph node cells from naive
mice and those treated or not with IFN-b were labeled with mAbs to CD28, CD80, and CD86, and the expression of these mol-
ecules was quantified by flow cytometry 24 h after the last treatment. The results are representative of eight experiments.
IU (total of 30,000 IU mouse in three doses). The results pre-
sented in Figure 4 are representative of eight experiments. The
data show that the expression of CTLA4 on the surface of leuko-
cytes increased significantly after administration of IFN-b com-
pared with that of those of the nontreated group. This increase
was observed for the expression of CTLA4 in CD41 cells
(1.52% 6 0.2% for nontreated group vs. 9.03% 6 0.9% for the
treated group, p , 0.001) and CD81 cells (2.6% 6 1.2% in the
nontreated group vs 7.56% 6 0.7% in the treated group, 
p , 0.001) (Fig. 4).
DISCUSSION
This study showed that the in vivo administration of IFN-b
to SJL mice reduces the severity of EAE by altering the ex-
pression of costimulatory molecules on leukocytes. As demon-
strated in Figure 1, administration of IFN-b markedly reduces
the clinical signs of EAE when given before the onset of the
disease. Treatment with IFN-b caused a stable, less severe form
of the disease, whereas the control animals continued to have
relapses of the acute form of the disease. These results are in
agreement with previous data demonstrating the beneficial ef-
fects of IFN-b in murine EAE.(3,4) The in vivo administration
of IFN-b also alters the in vitro immune response. As demon-
strated in Figure 2, administration of IFN-b inhibited the pro-
liferative response of lymph node T cells from MBP/CFA-
immunized mice and of spleen cells from nonimmunized ani-
mals stimulated with ConA. These results are also in agreement
with previous observations(3,19,20) indicating that IFN-b can
provide effective immunosuppression, resulting in inhibition of
the proliferative response of autoreactive T cells.
The role of costimulatory molecules in the maintenance and
loss of tolerance has been described.(21) T cell clones activated
solely by T cell receptor (TCR) binding to peptides and MHC
molecules without efficient costimulatory stimulation become
anergic.(19) Moreover, CTLA4/CD80/86 interactions may play
a role in the induction of anergy in the presence of low cos-
timulatory molecule expression.(20)
In the present study, a significant increase in the expression
of CD80 molecules in mice immunized with MBP was found
in relation to the normal expression of these molecules in naive
animals, but with IFN-b treatment, this was reduced to normal
levels. No significant changes in the expression of CD28 and
CD86 were observed. The role of CD80 in the development of
organ-specific autoimmune diseases, such as EAE and MS, in-
volves expression on activated microglia,(22,23) infiltrating mac-
rophages, and perivenular lymphocytes in active MS brain le-
sions, but not in normal brains, as previously described.(24)
Moreover, actively induced EAE in mice is prevented by treat-
ment with anti-CD80, whereas treatment with anti-CD86 anti-
body significantly worsened both clinical and histologic dis-
ease. The ability of anti-CD80/CD86 antibodies to inhibit or
enhance EAE relates to the capacities of these antibodies to ac-
tivate Th1 or Th2 cell cytokine.(13) The increase in anti-
inflammatory cytokine in vivo could be responsible for the de-
crease in CD80 expression, as it has been shown that IFN-b
enhances IL-10 and TGF-b production,(3,9) and these cytokines
decrease CD80/CD86 expression.(23,24) IFN-b also diminishes
the production of IFN-g, which in turn induces the expression
of CD80 and CD86 molecules.(25) MS patients treated with IFN-
b have shown decreased CD80 expression on circulating B
lymphocytes(26,27) and increased CD86 expression on mono-
cytes.(27) The in vitro addition of IFN-b upregulated the ex-
pression of CD80 and CD86 molecules in both dendritic and
monocyte cells.(28,29)
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FIG. 4. CTLA4 (CD152) expression on lymphocytes from SJL mice treated or not with IFN-b. The expression of CTLA4 was
quantified by flow cytometry on lymph node cells from SJL mice treated or not with IFN-b.
Concomitant with the reduction in CD80 molecule expres-
sion, IFN-b therapy was found to cause a moderate increase in
the early expression of CTLA4 molecules. Despite various re-
search efforts, the mechanisms by which CD28 and CTLA4 ex-
ert their effects remain poorly understood. There is some evi-
dence that CTLA4 may function, at least in part, by competing
with CD28 for CD80/86 ligands, thereby acting as an indirect
attenuator of costimulatory signals, and that the competition of
CTLA4 may be most effective when CD80/86 molecule levels
are low.(30) The CD28 molecule is constitutively expressed on
T cells, whereas CTLA4 is not readily detectable until 24–48
h after activation. The present data show that treatment with
IFN-b activated the early expression of CTLA4 in vivo, as the
cells analyzed here were not activated in vitro.
In recent years, various models have been proposed to ex-
plain whether CTLA4 might preexist, although expressed at low
levels, or can be induced rapidly even in naive cells on en-
gagement of the TCR and CD28.(30) This would be a possible
mechanism for ensuring peripheral tolerance by preventing ac-
tivation when a T cell encounters a self-antigen. The early ex-
pression of CTLA4 in T cells may also explain observations
that a CTLA4 blockade accelerates the onset of experimental
autoimmune diseases, including EAE.(14–16) We have demon-
strated that immunotherapy with IFN-b induces a moderate ex-
pression of CTLA4, but it is possible that even very low lev-
els of this molecule may be sufficient to bind to the CD80
molecule, which is reduced by the treatment. MBP-specific 
T cell activation might then be reduced, resulting in less severe
EAE.
We have demonstrated here that therapy with IFN-b
markedly reduces the expression of costimulatory molecules
(CD80) and increases CTLA4 expression. These observations
could explain, at least in part, the reduction of T lymphocyte
activation and, consequently, the beneficial effect of this treat-
ment in EAE.
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